New Delhi: Actuated by maturation in key emerging markets, India’s leading pharmaceutical company Ranbaxy Laboratories’ net profit for the quarter ended June 30 climbed up 118 percent to Rs 266.2 crore from Rs 122.11 crore in the corresponding period of the last year.
The company’s business in the rising market segments developed 44 per cent in the quarter, adding as much as 54 percent to its worldwide sales.
Torrent Pharma ascended 6.61% to Rs 257.95 and topped gainers in BSE’s ‘A’ group shares. The other gainers in the list were ABB, LIC Housing Finance, Reliance Energy and GMR Infrastructure.
Freshly, Torrent Pharma Ahmedabad based healthcare company had instigated Rimonabant, which is an anti-obesity molecule, for the first time in India under the trade name Rimoslim. The drug aims many cardio-metabolic risk factors that can lead to obesity, type 2 diabetes or dyslipidaemia.
New Delhi: Actuated by maturation in key emerging markets, India’s leading pharmaceutical company Ranbaxy Laboratories’ net profit for the quarter ended June 30 climbed up 118 percent to Rs 266.2 crore from Rs 122.11 crore in the corresponding period of the last year. 
ended June 2007, Biocon exposed a fantastic increase in net profits. 
has approved Lupin’s Abbreviated New Drug Application (ANDA) 
In early trade, Dabur Pharma was trading up 1.51% to Rs 77.50 after 50 lakh
ascended 6.61% to Rs 257.95 and topped gainers in BSE’s ‘A’ group shares. The other gainers in the list were ABB, LIC Housing Finance, Reliance Energy and GMR Infrastructure.
climbed up 1.05% to R
